Insmed Incorporated (INSM)
USD 64.81
(-4.06%)
USD 64.81
(-4.06%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.32 Billion USD | -19.72% |
| 2022 | 1.65 Billion USD | 33.21% |
| 2021 | 1.24 Billion USD | 56.19% |
| 2020 | 796.15 Million USD | 7.26% |
| 2019 | 742.29 Million USD | 22.78% |
| 2018 | 604.55 Million USD | 30.84% |
| 2017 | 462.04 Million USD | 94.17% |
| 2016 | 237.95 Million USD | -33.26% |
| 2015 | 356.55 Million USD | 54.44% |
| 2014 | 230.86 Million USD | 30.8% |
| 2013 | 176.49 Million USD | 14.94% |
| 2012 | 153.56 Million USD | 9.82% |
| 2011 | 139.83 Million USD | -28.75% |
| 2010 | 196.26 Million USD | 54.91% |
| 2009 | 126.69 Million USD | 2562.78% |
| 2008 | 4.75 Million USD | -75.6% |
| 2007 | 19.5 Million USD | -31.21% |
| 2006 | 28.34 Million USD | 23.95% |
| 2005 | 22.87 Million USD | 75.77% |
| 2004 | 13.01 Million USD | -56.36% |
| 2003 | 29.81 Million USD | 5.31% |
| 2002 | 28.3 Million USD | -60.47% |
| 2001 | 71.6 Million USD | -30.29% |
| 2000 | 102.71 Million USD | 1839.71% |
| 1999 | 5.29 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 2.05 Billion USD | 13.42% |
| 2024 Q2 | 1.81 Billion USD | 56.17% |
| 2024 Q1 | 1.15 Billion USD | -12.84% |
| 2023 Q1 | 1.51 Billion USD | -8.37% |
| 2023 FY | 1.32 Billion USD | -19.72% |
| 2023 Q3 | 1.32 Billion USD | -7.94% |
| 2023 Q4 | 1.32 Billion USD | 0.37% |
| 2023 Q2 | 1.43 Billion USD | -5.18% |
| 2022 Q4 | 1.65 Billion USD | 66.51% |
| 2022 Q2 | 1.05 Billion USD | -8.67% |
| 2022 Q1 | 1.15 Billion USD | -7.25% |
| 2022 FY | 1.65 Billion USD | 33.21% |
| 2022 Q3 | 994.81 Million USD | -5.56% |
| 2021 Q3 | 1.31 Billion USD | 6.67% |
| 2021 FY | 1.24 Billion USD | 56.19% |
| 2021 Q1 | 692.39 Million USD | -13.03% |
| 2021 Q2 | 1.22 Billion USD | 77.61% |
| 2021 Q4 | 1.24 Billion USD | -5.2% |
| 2020 FY | 796.15 Million USD | 7.26% |
| 2020 Q1 | 676.52 Million USD | -8.86% |
| 2020 Q2 | 885.36 Million USD | 30.87% |
| 2020 Q3 | 840.71 Million USD | -5.04% |
| 2020 Q4 | 796.15 Million USD | -5.3% |
| 2019 Q2 | 802.78 Million USD | 34.71% |
| 2019 Q3 | 763.11 Million USD | -4.94% |
| 2019 Q4 | 742.29 Million USD | -2.73% |
| 2019 Q1 | 595.91 Million USD | -1.43% |
| 2019 FY | 742.29 Million USD | 22.78% |
| 2018 FY | 604.55 Million USD | 30.84% |
| 2018 Q4 | 604.55 Million USD | -8.61% |
| 2018 Q3 | 661.51 Million USD | -8.66% |
| 2018 Q2 | 724.24 Million USD | -6.33% |
| 2018 Q1 | 773.15 Million USD | 67.33% |
| 2017 Q4 | 462.04 Million USD | -8.72% |
| 2017 Q3 | 506.2 Million USD | 205.61% |
| 2017 Q2 | 165.64 Million USD | -17.45% |
| 2017 Q1 | 200.65 Million USD | -15.67% |
| 2017 FY | 462.04 Million USD | 94.17% |
| 2016 Q3 | 276.64 Million USD | -7.69% |
| 2016 FY | 237.95 Million USD | -33.26% |
| 2016 Q4 | 237.95 Million USD | -13.98% |
| 2016 Q2 | 299.67 Million USD | -8.55% |
| 2016 Q1 | 327.7 Million USD | -8.09% |
| 2015 Q3 | 385.74 Million USD | -5.57% |
| 2015 Q1 | 206.15 Million USD | -10.7% |
| 2015 FY | 356.55 Million USD | 54.44% |
| 2015 Q2 | 408.5 Million USD | 98.16% |
| 2015 Q4 | 356.55 Million USD | -7.57% |
| 2014 Q2 | 150.11 Million USD | -9.91% |
| 2014 Q3 | 235.44 Million USD | 56.85% |
| 2014 Q4 | 230.86 Million USD | -1.94% |
| 2014 FY | 230.86 Million USD | 30.8% |
| 2014 Q1 | 166.62 Million USD | -5.6% |
| 2013 Q1 | 143.01 Million USD | -6.87% |
| 2013 Q4 | 176.49 Million USD | -7.08% |
| 2013 FY | 176.49 Million USD | 14.94% |
| 2013 Q3 | 189.95 Million USD | 36.93% |
| 2013 Q2 | 138.72 Million USD | -3.0% |
| 2012 Q4 | 153.56 Million USD | 0.72% |
| 2012 Q2 | 136.05 Million USD | 2.1% |
| 2012 Q1 | 133.25 Million USD | -4.71% |
| 2012 FY | 153.56 Million USD | 9.82% |
| 2012 Q3 | 152.45 Million USD | 12.06% |
| 2011 Q1 | 190.47 Million USD | -2.95% |
| 2011 FY | 139.83 Million USD | -28.75% |
| 2011 Q4 | 139.83 Million USD | -4.27% |
| 2011 Q3 | 146.06 Million USD | -18.98% |
| 2011 Q2 | 180.28 Million USD | -5.35% |
| 2010 Q1 | 126.89 Million USD | 0.15% |
| 2010 Q2 | 127.4 Million USD | 0.41% |
| 2010 Q4 | 196.26 Million USD | 54.54% |
| 2010 Q3 | 127 Million USD | -0.32% |
| 2010 FY | 196.26 Million USD | 54.91% |
| 2009 Q1 | 129.82 Million USD | 2628.46% |
| 2009 Q2 | 125.3 Million USD | -3.48% |
| 2009 Q3 | 124.62 Million USD | -0.54% |
| 2009 Q4 | 126.69 Million USD | 1.66% |
| 2009 FY | 126.69 Million USD | 2562.78% |
| 2008 FY | 4.75 Million USD | -75.6% |
| 2008 Q2 | 11.95 Million USD | -19.28% |
| 2008 Q3 | 8.14 Million USD | -31.85% |
| 2008 Q4 | 4.75 Million USD | -41.61% |
| 2008 Q1 | 14.81 Million USD | -24.04% |
| 2007 Q1 | 15.7 Million USD | -44.59% |
| 2007 Q2 | 25.92 Million USD | 65.03% |
| 2007 Q4 | 19.5 Million USD | -13.65% |
| 2007 FY | 19.5 Million USD | -31.21% |
| 2007 Q3 | 22.58 Million USD | -12.89% |
| 2006 Q1 | 62.64 Million USD | 173.9% |
| 2006 Q4 | 28.34 Million USD | -37.12% |
| 2006 Q3 | 45.08 Million USD | -20.71% |
| 2006 Q2 | 56.85 Million USD | -9.24% |
| 2006 FY | 28.34 Million USD | 23.95% |
| 2005 Q4 | 22.87 Million USD | -11.15% |
| 2005 FY | 22.87 Million USD | 75.77% |
| 2005 Q3 | 25.74 Million USD | -23.7% |
| 2005 Q1 | 41.12 Million USD | 216.08% |
| 2005 Q2 | 33.73 Million USD | -17.97% |
| 2004 FY | 13.01 Million USD | -56.36% |
| 2004 Q1 | 25.33 Million USD | -15.01% |
| 2004 Q2 | 18.86 Million USD | -25.57% |
| 2004 Q3 | 11.6 Million USD | -38.46% |
| 2004 Q4 | 13.01 Million USD | 12.1% |
| 2003 Q2 | 22.57 Million USD | -11.02% |
| 2003 Q3 | 32.61 Million USD | 44.46% |
| 2003 Q4 | 29.81 Million USD | -8.58% |
| 2003 FY | 29.81 Million USD | 5.31% |
| 2003 Q1 | 25.37 Million USD | -10.38% |
| 2002 Q2 | 55.3 Million USD | -11.71% |
| 2002 Q3 | 49.34 Million USD | -10.78% |
| 2002 FY | 28.3 Million USD | -60.47% |
| 2002 Q1 | 62.63 Million USD | -12.52% |
| 2002 Q4 | 28.3 Million USD | -42.63% |
| 2001 Q1 | 93.23 Million USD | -9.23% |
| 2001 Q3 | 77.81 Million USD | -9.91% |
| 2001 Q4 | 71.6 Million USD | -7.97% |
| 2001 FY | 71.6 Million USD | -30.29% |
| 2001 Q2 | 86.36 Million USD | -7.37% |
| 2000 Q3 | 50.15 Million USD | -2.63% |
| 2000 Q1 | 6.64 Million USD | 0.0% |
| 2000 FY | 102.71 Million USD | 1839.71% |
| 2000 Q2 | 51.5 Million USD | 675.36% |
| 2000 Q4 | 102.71 Million USD | 104.82% |
| 1999 FY | 5.29 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Keros Therapeutics, Inc. | 370.02 Million USD | -259.391% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 65.277% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | -59.632% |
| AlloVir, Inc. | 190.79 Million USD | -596.994% |
| Precigen, Inc. | 151.04 Million USD | -780.436% |
| Avidity Biosciences, Inc. | 628.55 Million USD | -111.571% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -25623.673% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -6927.372% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -2836.465% |
| Acelyrin, Inc. | 742.69 Million USD | -79.057% |
| AbCellera Biologics Inc. | 1.48 Billion USD | 10.635% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | -181.245% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -2245.723% |
| Agenus Inc. | 313.91 Million USD | -323.632% |
| Dyadic International, Inc. | 8.21 Million USD | -16079.569% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -4089.783% |
| Lantern Pharma Inc. | 43.64 Million USD | -2946.757% |
| Immix Biopharma, Inc. | 19.92 Million USD | -6574.16% |
| IO Biotech, Inc. | 150.71 Million USD | -782.335% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -4017.015% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -690.751% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -519.953% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -904.234% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | -450.195% |
| Alkermes plc | 2.13 Billion USD | 37.748% |
| Aptorum Group Limited | 20.64 Million USD | -6342.98% |
| Ardelyx, Inc. | 297.57 Million USD | -346.885% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | -73.71% |
| Bicycle Therapeutics plc | 595.34 Million USD | -123.373% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -1704.343% |
| Chimerix, Inc. | 212.77 Million USD | -525.0% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -4603.659% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 40.355% |
| Elevation Oncology, Inc. | 89.09 Million USD | -1392.673% |
| ESSA Pharma Inc. | 149.12 Million USD | -791.777% |
| Fortress Biotech, Inc. | 167.52 Million USD | -693.809% |
| Fortress Biotech, Inc. | 167.52 Million USD | -693.809% |
| NextCure, Inc. | 129.41 Million USD | -927.552% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -2365.035% |
| Onconetix, Inc. | 88.82 Million USD | -1397.203% |
| Opthea Limited | 188.79 Million USD | -604.396% |
| PDS Biotechnology Corporation | 59.39 Million USD | -2139.157% |
| GT Biopharma, Inc. | 14.1 Million USD | -9325.452% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -724.26% |
| ImmuCell Corporation | 43.8 Million USD | -2935.596% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | -104.806% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -9067.087% |
| Incyte Corporation | 6.78 Billion USD | 80.392% |
| Jaguar Health, Inc. | 50.76 Million USD | -2519.697% |
| Janux Therapeutics, Inc. | 380.4 Million USD | -249.583% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -21342.067% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -2523.108% |
| ContextLogic Inc. | 423 Million USD | -214.382% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | -107.61% |
| MiMedx Group, Inc. | 239.04 Million USD | -456.308% |
| MEI Pharma, Inc. | 41.37 Million USD | -3114.108% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -665.48% |
| Seer, Inc. | 436.26 Million USD | -204.82% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -20090.273% |
| Novavax, Inc. | 1.85 Billion USD | 28.324% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -3809.216% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -3520.673% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -1261.352% |
| Wave Life Sciences Ltd. | 274.94 Million USD | -383.667% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | -290.213% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -117360.268% |
| Vaxcyte, Inc. | 1.4 Billion USD | 5.546% |
| C4 Therapeutics, Inc. | 376.45 Million USD | -253.256% |
| Pharming Group N.V. | 462.85 Million USD | -187.312% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | -221.339% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -3338.048% |
| PureTech Health plc | 693.97 Million USD | -91.627% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -1034.431% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -6927.372% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -704.402% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -20668.968% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -1688.04% |
| Senti Biosciences, Inc. | 119.48 Million USD | -1012.983% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -482.388% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -15993.876% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -27757.177% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | -183.431% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -1529.762% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -975.459% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -4003.675% |
| ChromaDex Corporation | 54.96 Million USD | -2319.469% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -13060.188% |
| Caribou Biosciences, Inc. | 440.96 Million USD | -201.572% |
| Precision BioSciences, Inc. | 159.78 Million USD | -732.287% |
| Fate Therapeutics, Inc. | 506.21 Million USD | -162.701% |
| Innoviva, Inc. | 1.24 Billion USD | -6.942% |
| Summit Therapeutics Inc. | 202.94 Million USD | -555.257% |
| GlycoMimetics, Inc. | 45.31 Million USD | -2834.555% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | -331.915% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | -181.801% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -1296.712% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -210454.507% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | -134.812% |
| Aptose Biosciences Inc. | 12.92 Million USD | -10190.83% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -5913.475% |
| Soligenix, Inc. | 9.79 Million USD | -13473.469% |
| Century Therapeutics, Inc. | 360.69 Million USD | -268.691% |
| Kura Oncology, Inc. | 448.93 Million USD | -196.22% |
| TScan Therapeutics, Inc. | 272.14 Million USD | -388.643% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -7589.141% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -1099.009% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -548.224% |
| Autolus Therapeutics plc | 375.38 Million USD | -254.263% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | -428.476% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | -274.408% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -2606.662% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | -101.145% |
| GRI Bio, Inc. | 2.95 Million USD | -44887.72% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -12439.45% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -679.894% |
| IGM Biosciences, Inc. | 423.41 Million USD | -214.077% |
| INmune Bio, Inc. | 57 Million USD | -2233.006% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -497.663% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -1484.247% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -4991.872% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -19220.054% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -1667.789% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -803.066% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -703.507% |
| Coherus BioSciences, Inc. | 629.6 Million USD | -111.218% |
| Verastem, Inc. | 149.71 Million USD | -788.228% |
| Abeona Therapeutics Inc. | 64 Million USD | -1977.805% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | -159.656% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -760.976% |
| Histogen Inc. | 19.07 Million USD | -6872.354% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -5771.2% |
| Surrozen, Inc. | 46.08 Million USD | -2785.931% |
| Organovo Holdings, Inc. | 6.34 Million USD | -20845.613% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -30764.569% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -823.326% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -11167.895% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -1666.803% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -15509.79% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | -266.378% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -7249.441% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | -209.695% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -10444.454% |
| Apollomics, Inc. | 55.38 Million USD | -2300.991% |
| Amarin Corporation plc | 831.68 Million USD | -59.897% |
| Mesoblast Limited | 669.15 Million USD | -98.734% |
| Turnstone Biologics Corp. | 112.81 Million USD | -1078.777% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | -130.971% |
| Synaptogenix, Inc. | 31.11 Million USD | -4174.125% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -10814.618% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | -142.644% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -22546.081% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -18004.945% |
| Exelixis, Inc. | 2.94 Billion USD | 54.804% |
| Better Therapeutics, Inc. | 22.94 Million USD | -5696.265% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | -264.8% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | -68.605% |
| NLS Pharmaceutics AG | 1.84 Million USD | -71913.835% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -16567.477% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -8949.588% |
| Gritstone bio, Inc. | 177.76 Million USD | -648.07% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -1294.251% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -7344.95% |
| Avid Bioservices, Inc. | 336.55 Million USD | -295.13% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -13711.688% |
| MediWound Ltd. | 66.45 Million USD | -1900.989% |
| OmniAb, Inc. | 401.98 Million USD | -230.818% |
| Alector, Inc. | 621.82 Million USD | -113.86% |
| Seres Therapeutics, Inc. | 358.6 Million USD | -270.841% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -24627.352% |
| Zai Lab Limited | 1.03 Billion USD | -28.326% |
| Revance Therapeutics, Inc. | 478.45 Million USD | -177.945% |
| Aura Biosciences, Inc. | 255.07 Million USD | -421.351% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | -77.305% |
| Immunic, Inc. | 54.29 Million USD | -2349.1% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | -399.518% |
| Veracyte, Inc. | 1.13 Billion USD | -16.876% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -11148.089% |
| FibroGen, Inc. | 423.52 Million USD | -213.99% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -37754.74% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -27975.742% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -24392.907% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 88.328% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -15003.203% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | -156.996% |
| TG Therapeutics, Inc. | 329.58 Million USD | -303.486% |
| Galecto, Inc. | 38.22 Million USD | -3378.79% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -4537.456% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 69.48% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | -464.917% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -5253.18% |
| XBiotech Inc. | 227.24 Million USD | -485.205% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -1294.251% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -832.565% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | -365.115% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -940.0% |
| Theravance Biopharma, Inc. | 381.99 Million USD | -248.126% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 10.81% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | -264.497% |
| Vaxxinity, Inc. | 44.35 Million USD | -2898.302% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | -157.242% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -7046.076% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | -335.941% |
| NexImmune, Inc. | 8.59 Million USD | -15374.109% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -12310.765% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -7664.387% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 95.98% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -5903.472% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -338914.952% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -667.233% |
| Ainos, Inc. | 31.84 Million USD | -4076.387% |
| Pluri Inc. | 39.52 Million USD | -3264.376% |
| Prothena Corporation plc | 696.38 Million USD | -90.964% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | -370.546% |
| Celularity Inc. | 143.88 Million USD | -824.21% |
| Rallybio Corporation | 115.62 Million USD | -1050.179% |
| Cue Biopharma, Inc. | 61.53 Million USD | -2061.282% |
| MeiraGTx Holdings plc | 458.16 Million USD | -190.251% |
| Omeros Corporation | 378.26 Million USD | -251.559% |
| Humacyte, Inc. | 128.22 Million USD | -937.128% |
| Immunocore Holdings plc | 597 Million USD | -122.753% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -4154.253% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -1840.518% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -26.742% |
| CalciMedica, Inc. | 12.18 Million USD | -10813.722% |
| Cabaletta Bio, Inc. | 253.65 Million USD | -424.28% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -678.101% |
| Scholar Rock Holding Corporation | 311.03 Million USD | -327.552% |
| Sana Biotechnology, Inc. | 565.29 Million USD | -135.245% |
| Pulmatrix, Inc. | 33.95 Million USD | -3816.123% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -4798.832% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -844.098% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | -2.218% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -921.466% |
| Cytokinetics, Incorporated | 824.31 Million USD | -61.326% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -6195.682% |
| Nutriband Inc. | 7.51 Million USD | -17590.698% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -1584.319% |
| Vor Biopharma Inc. | 209.82 Million USD | -533.775% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 81.588% |
| Evogene Ltd. | 51.1 Million USD | -2502.37% |
| ProKidney Corp. | 420.55 Million USD | -216.212% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -2325.249% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -13868.468% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | -143.39% |
| CorMedix Inc. | 82.05 Million USD | -1520.568% |
| BioLineRx Ltd. | 63.92 Million USD | -1980.308% |
| Tango Therapeutics, Inc. | 402.56 Million USD | -230.339% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -4615.734% |
| Atai Life Sciences N.V. | 293.47 Million USD | -353.13% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -715.204% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -943.681% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | -136.614% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -1274.949% |
| MediciNova, Inc. | 66.26 Million USD | -1906.696% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -1412.072% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -29701.17% |
| GeoVax Labs, Inc. | 9.28 Million USD | -14225.171% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -126.072% |
| Biomea Fusion, Inc. | 199.92 Million USD | -565.161% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 30.126% |
| Mereo BioPharma Group plc | 66.49 Million USD | -1899.785% |
| Cullinan Oncology, Inc. | 485.09 Million USD | -174.139% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | -116.982% |
| Absci Corporation | 234.48 Million USD | -467.143% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -18079.59% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | -291.254% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -705.561% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | -152.666% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | -378.887% |
| Allakos Inc. | 243.61 Million USD | -445.888% |
| Imunon, Inc. | 21.91 Million USD | -5967.309% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | -416.053% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -113.966% |
| BioAtla, Inc. | 119.65 Million USD | -1011.365% |
| NLS Pharmaceutics AG | 1.84 Million USD | -71913.835% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -41199.286% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | -106.87% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -1286.185% |
| XOMA Corporation | 234.3 Million USD | -467.576% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -501.097% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -956.735% |
| aTyr Pharma, Inc. | 122.06 Million USD | -989.432% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -764.075% |
| Akero Therapeutics, Inc. | 580.27 Million USD | -129.175% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | -171.161% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -1103.81% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -8673.425% |
| Akari Therapeutics, Plc | 4.35 Million USD | -30435.867% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -7705.429% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 23.276% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -43020.721% |
| UroGen Pharma Ltd. | 178.31 Million USD | -645.796% |
| Sutro Biopharma, Inc. | 470.73 Million USD | -182.502% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -239201.98% |
| Orgenesis Inc. | 14.55 Million USD | -9038.517% |
| Entera Bio Ltd. | 11.76 Million USD | -11203.332% |
| GH Research PLC | 226.3 Million USD | -487.643% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -2331.413% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -1137.795% |
| Xencor, Inc. | 952.69 Million USD | -39.587% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -16984.74% |
| Replimune Group, Inc. | 487.72 Million USD | -172.663% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -16376.55% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | -105.083% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -43020.721% |
| Portage Biotech Inc. | 7.77 Million USD | -16995.218% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -29701.17% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | -380.181% |
| OncoCyte Corporation | 74.89 Million USD | -1675.673% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -65304.565% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -22881.148% |
| Purple Biotech Ltd. | 44.3 Million USD | -2901.754% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -3796.844% |
| scPharmaceuticals Inc. | 94.47 Million USD | -1307.548% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -7269.577% |
| HilleVax, Inc. | 344.43 Million USD | -286.093% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -41771.442% |
| Tharimmune, Inc. | 10.94 Million USD | -12048.632% |
| Genprex, Inc. | 10.67 Million USD | -12362.636% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | -168.007% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -1281.62% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -54716.035% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -31825.479% |
| OKYO Pharma Limited | 1.54 Million USD | -86182.233% |
| Savara Inc. | 177.56 Million USD | -648.934% |
| Curis, Inc. | 77.28 Million USD | -1620.759% |
| Daré Bioscience, Inc. | 21.28 Million USD | -6148.584% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -1979.534% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -16346.166% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -6765.092% |
| BeiGene, Ltd. | 5.8 Billion USD | 77.093% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -10828.071% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 36.329% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | -271.514% |
| Erasca, Inc. | 395.29 Million USD | -236.415% |
| bluebird bio, Inc. | 619.16 Million USD | -114.78% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -30659.276% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 80.562% |
| DBV Technologies S.A. | 182.98 Million USD | -626.742% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -30659.276% |
| Moderna, Inc. | 18.42 Billion USD | 92.783% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -7199.978% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -11377.965% |
| Molecular Templates, Inc. | 35.38 Million USD | -3658.407% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -861.803% |
| Travere Therapeutics, Inc. | 788.91 Million USD | -68.566% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | -337.799% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -1179.354% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | -185.601% |
| Cogent Biosciences, Inc. | 313.43 Million USD | -324.276% |
| MacroGenics, Inc. | 306.82 Million USD | -333.426% |
| RenovoRx, Inc. | 1.46 Million USD | -90611.937% |
| Adicet Bio, Inc. | 207.29 Million USD | -541.519% |
| Prime Medicine, Inc. | 193.85 Million USD | -586.01% |
| Aditxt, Inc. | 44.57 Million USD | -2883.147% |
| Adagene Inc. | 115.72 Million USD | -1049.097% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -29755.873% |
| Quantum-Si incorporated | 298.25 Million USD | -345.88% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 10.596% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -17150.172% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | -278.568% |
| SciSparc Ltd. | 11.18 Million USD | -11792.658% |
| Vericel Corporation | 353.65 Million USD | -276.025% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -10789.049% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -2237.122% |
| Generation Bio Co. | 374.75 Million USD | -254.852% |
| Astria Therapeutics, Inc. | 254.66 Million USD | -422.189% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -738.659% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | -289.565% |
| Invivyd, Inc. | 229.18 Million USD | -480.256% |
| Relay Therapeutics, Inc. | 843.98 Million USD | -57.567% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -10827.801% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -629.117% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -6411.149% |
| 2seventy bio, Inc. | 565.42 Million USD | -135.192% |
| ADMA Biologics, Inc. | 329.18 Million USD | -303.982% |
| Clene Inc. | 52.34 Million USD | -2440.718% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -2164.156% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -923.786% |
| GeoVax Labs, Inc. | 9.28 Million USD | -14225.171% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | -103.433% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -1183.488% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -919.923% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -1263.208% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -1773.089% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | -448.267% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 32.154% |
| Evaxion Biotech A/S | 12.88 Million USD | -10217.917% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | -427.587% |
| Verve Therapeutics, Inc. | 752.68 Million USD | -76.678% |
| Trevena, Inc. | 40.6 Million USD | -3175.057% |
| Surrozen, Inc. | 46.08 Million USD | -2785.931% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -488.796% |
| Cingulate Inc. | 3.49 Million USD | -37988.54% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -7897.095% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -1924.413% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -11281.082% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | -395.252% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | -77.559% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -956.332% |
| Clearmind Medicine Inc. | 4.32 Million USD | -30652.021% |
| Kronos Bio, Inc. | 213.27 Million USD | -523.52% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -732.272% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -15434.372% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -260.888% |
| Statera Biopharma, Inc. | 21.16 Million USD | -6181.799% |
| ImmunityBio, Inc. | 504.45 Million USD | -163.62% |
| Korro Bio, Inc. | 221.66 Million USD | -499.936% |
| Kineta, Inc. | 10.28 Million USD | -12834.899% |
| BioVie Inc. | 25.2 Million USD | -5175.384% |
| Codexis, Inc. | 136.56 Million USD | -873.804% |
| Celularity Inc. | 143.88 Million USD | -824.21% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | -109.307% |
| Celcuity Inc. | 191.21 Million USD | -595.451% |
| Virax Biolabs Group Limited | 5.48 Million USD | -24149.535% |
| Cibus, Inc. | 544.41 Million USD | -144.271% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -956.315% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -6373.116% |
| IN8bio, Inc. | 33.7 Million USD | -3845.05% |
| Kodiak Sciences Inc. | 479.37 Million USD | -177.412% |
| Annexon, Inc. | 297.67 Million USD | -346.743% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -668.647% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -867.372% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -6234.669% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 55.525% |
| Eyenovia, Inc. | 28.77 Million USD | -4520.799% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -476.866% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -18308.596% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -2082.709% |
| Arcellx, Inc. | 825.13 Million USD | -61.167% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -1528.964% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | -187.672% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -4224.673% |
| Moolec Science SA | 24.05 Million USD | -5429.171% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | -328.807% |
| Geron Corporation | 394.07 Million USD | -237.457% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -1207.479% |
| Royalty Pharma plc | 16.38 Billion USD | 91.882% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | -123.514% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -18911.754% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -10956.806% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -488.267% |
| Humacyte, Inc. | 128.22 Million USD | -937.128% |
| Structure Therapeutics Inc. | 482.01 Million USD | -175.89% |
| 89bio, Inc. | 596.26 Million USD | -123.026% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | -427.395% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -71783.081% |
| Genelux Corporation | 27.89 Million USD | -4667.637% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -1387.464% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -479.629% |
| Notable Labs, Ltd. | 19.54 Million USD | -6705.368% |
| Liquidia Corporation | 120.43 Million USD | -1004.231% |
| Mustang Bio, Inc. | 17.74 Million USD | -7395.418% |
| Immunovant, Inc. | 666.71 Million USD | -99.462% |
| Quantum-Si incorporated | 298.25 Million USD | -345.88% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -820.933% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -2355.386% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -657.543% |
| Acasti Pharma Inc. | 73.3 Million USD | -1714.239% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -29112.542% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -4991.872% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | -37.836% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -25523.468% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -5737.483% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -2477.054% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -635.973% |
| PepGen Inc. | 143.05 Million USD | -829.618% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -3379.7% |
| United Therapeutics Corporation | 7.16 Billion USD | 81.445% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -6831.65% |
| Solid Biosciences Inc. | 164.93 Million USD | -706.26% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -22546.081% |
| Immuneering Corporation | 102.58 Million USD | -1196.333% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -30764.569% |
| Silo Pharma, Inc. | 7.74 Million USD | -17067.736% |
| Belite Bio, Inc | 94.64 Million USD | -1305.124% |
| XOMA Corporation | 234.3 Million USD | -467.576% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -470.285% |
| Bionomics Limited | 27.64 Million USD | -4709.695% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | -231.296% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -1138.348% |
| uniQure N.V. | 831.68 Million USD | -59.896% |
| Cassava Sciences, Inc. | 151.66 Million USD | -776.837% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -29755.873% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | -385.546% |
| Forte Biosciences, Inc. | 38.98 Million USD | -3311.588% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -32549.148% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -3510.646% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -18308.596% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -37754.74% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -11149.784% |
| Altimmune, Inc. | 210.64 Million USD | -531.332% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -70.957% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -1138.348% |
| Compugen Ltd. | 121.33 Million USD | -996.013% |
| Peak Bio, Inc. | 2.59 Million USD | -51118.199% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -671.694% |
| Benitec Biopharma Inc. | 52.21 Million USD | -2447.093% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | -289.002% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -3724.338% |
| Zura Bio Limited | 100.84 Million USD | -1218.72% |
| PolyPid Ltd. | 15.37 Million USD | -8551.034% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -1014.831% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -3724.338% |
| Instil Bio, Inc. | 325.63 Million USD | -308.389% |
| argenx SE | 4.54 Billion USD | 70.724% |
| Immunome, Inc. | 148.54 Million USD | -795.272% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -747.705% |
| Verona Pharma plc | 308.12 Million USD | -331.592% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -1429.269% |
| Shattuck Labs, Inc. | 159.56 Million USD | -733.419% |
| CervoMed Inc. | 9.97 Million USD | -13235.013% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -605.649% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -11577.529% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -641.249% |
| Moolec Science SA | 24.05 Million USD | -5429.171% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -21638.314% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -668.939% |
| AnaptysBio, Inc. | 452.38 Million USD | -193.959% |
| Design Therapeutics, Inc. | 289.64 Million USD | -359.13% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -1726.072% |
| NeurAxis, Inc. | 509.49 Thousand USD | -260909.268% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -24444.795% |
| Lumos Pharma, Inc. | 40.63 Million USD | -3172.398% |
| Achilles Therapeutics plc | 161.45 Million USD | -723.653% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -1429.269% |
| 180 Life Sciences Corp. | 5.25 Million USD | -25184.591% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -1788.227% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -15434.372% |
| Nutriband Inc. | 7.51 Million USD | -17590.698% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | -422.148% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -567.251% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -1644.918% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -2196.148% |
| MoonLake Immunotherapeutics | 526.54 Million USD | -152.561% |
| Palisade Bio, Inc. | 14.05 Million USD | -9363.685% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -532.367% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 8.897% |
| Neurogene Inc. | 222.57 Million USD | -497.484% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | -105.659% |
| AEON Biopharma, Inc. | 6.84 Million USD | -19327.86% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | -193.539% |
| Sesen Bio, Inc. | 189.17 Million USD | -602.97% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | -389.15% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -9598.436% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -70.415% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | -398.077% |
| Athira Pharma, Inc. | 160.24 Million USD | -729.877% |
| Vaccinex, Inc. | 3.63 Million USD | -36524.539% |
| HCW Biologics Inc. | 28.51 Million USD | -4563.859% |
| XOMA Corporation | 234.3 Million USD | -467.576% |
| Nektar Therapeutics | 398.03 Million USD | -234.102% |
| Arvinas, Inc. | 1.3 Billion USD | -1.934% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -7705.429% |
| Merus N.V. | 458.49 Million USD | -190.045% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -550.713% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -637.962% |
| Rezolute, Inc. | 132.73 Million USD | -901.859% |
| Clene Inc. | 52.34 Million USD | -2440.718% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -8810.801% |
| BeyondSpring Inc. | 24.8 Million USD | -5260.517% |
| Synlogic, Inc. | 75.55 Million USD | -1660.208% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -11110.9% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -14101.591% |
| Peak Bio, Inc. | 2.59 Million USD | -51118.199% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -660.633% |
| Krystal Biotech, Inc. | 818.35 Million USD | -62.501% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | -453.089% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | -83.227% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -37075.631% |
| MannKind Corporation | 475.19 Million USD | -179.849% |
| Ikena Oncology, Inc. | 192.09 Million USD | -592.292% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -9843.45% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -1041.109% |
| Gossamer Bio, Inc. | 311.91 Million USD | -326.345% |
| CohBar, Inc. | 16.36 Million USD | -8025.773% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -3681.921% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -18079.59% |
| Legend Biotech Corporation | 1.84 Billion USD | 28.063% |
| Mural Oncology plc | 301.74 Million USD | -340.716% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -4160.25% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -23310.954% |
| Disc Medicine, Inc. | 367.99 Million USD | -261.373% |
| Champions Oncology, Inc. | 26.13 Million USD | -4988.922% |
| REGENXBIO Inc. | 573.97 Million USD | -131.691% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -49006.177% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -761.371% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -10912.614% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | -291.088% |
| Vaxart, Inc. | 91.83 Million USD | -1348.151% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -2119.951% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -796.558% |
| Cellectis S.A. | 334.27 Million USD | -297.833% |
| Longeveron Inc. | 12.17 Million USD | -10819.995% |
| Repare Therapeutics Inc. | 253.9 Million USD | -423.762% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 59.265% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -562.114% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 36.329% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -81736.123% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | -378.856% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -715.361% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -858.483% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -5110.552% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 94.149% |
| Denali Therapeutics Inc. | 1.15 Billion USD | -15.245% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -10789.049% |
| Veru Inc. | 50.59 Million USD | -2528.348% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -2819.318% |
| Cingulate Inc. | 3.49 Million USD | -37988.54% |
| Passage Bio, Inc. | 150.54 Million USD | -783.349% |
| Context Therapeutics Inc. | 16.06 Million USD | -8179.02% |
| Exicure, Inc. | 11.58 Million USD | -11383.912% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | -253.635% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -722.705% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -7511.247% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | -299.656% |
| Nuvalent, Inc. | 732.38 Million USD | -81.576% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -8798.755% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -1384.955% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -9270.989% |
| OmniAb, Inc. | 401.98 Million USD | -230.818% |
| Anew Medical, Inc. | 19.45 Million USD | -6735.116% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -4875.714% |
| Lipocine Inc. | 23 Million USD | -5681.631% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -851.195% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | -335.206% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -1484.247% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -994.156% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -16659.13% |
| Sage Therapeutics, Inc. | 882.27 Million USD | -50.728% |
| Ocugen, Inc. | 64.54 Million USD | -1960.262% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -967.791% |
| Q32 Bio Inc. | 306.11 Million USD | -334.418% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -31502.59% |
| Alumis Inc. Common Stock | 89.61 Million USD | -1383.994% |
| Equillium, Inc. | 50.53 Million USD | -2531.777% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -1668.518% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -3122.01% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -78086.475% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -4987.17% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -1963.65% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -35580.083% |
| Dominari Holdings Inc. | 57.55 Million USD | -2210.429% |
| Edesa Biotech, Inc. | 8.89 Million USD | -14858.061% |
| vTv Therapeutics Inc. | 11.01 Million USD | -11969.677% |
| Bio-Techne Corporation | 2.81 Billion USD | 52.729% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -41.907% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | -63.884% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | -378.936% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -3088.905% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | -99.2% |
| Nkarta, Inc. | 378.88 Million USD | -250.987% |
| BioCardia, Inc. | 2.98 Million USD | -44420.824% |
| Iterum Therapeutics plc | 26.25 Million USD | -4964.309% |